[无症状体征过程的CADASIL患者的治疗耐药性慢性抑郁症:一个病例报告]
Sebastian Wurthmann1,2, Oliver Kastrup3, Cornelius Wurthmann4
1LVR-Universitätsklinik Essen, Klinik für Psychiatrie und Psychotherapie Essen, Essen, Germany.
Fortschritte der Neurologie-Psychiatrie
|February 7, 2025
概括
大脑自体主导性动脉病变与皮层下心脏病发作和白细胞大脑病变 (CADASIL) 可能仅表现出精神症状,即使具有特定的遗传突变. 这突显了考虑CADASIL在治疗耐药抑郁症和脑成像变化的重要性.
科学领域:
- 神经学 神经学
- 遗传学 遗传学 是一个
- 精神病学是一个精神病学.
背景情况:
- 抑郁症是常见的,但需要特别注意,当治疗耐药和与神经成像发现相关时.
- 大脑自体主导性动脉病变与皮下心脏病发作和白细胞脑病变 (CADASIL) 是一种罕见的遗传小血管疾病.
- 卡达西尔通常表现为中风,头痛,精神病和认知问题.
研究的目的:
- 报告CADASIL的独特病例,呈现出长期的精神症状.
- 为了强调CADASIL的表型异质性.
- 建议在特定的临床场景中考虑CADASIL.
主要方法:
- 一个63岁的病人的病例报告,有20年的严重情感症状史.
- 在EGFr 4域中识别致病性NOTCH3基因变异的基因测试.
- 神经成像显示特征变化.
主要成果:
- 患者仅表现出精神症状,缺乏经典的CADASIL体质特征.
- 在NOTCH3 EGFr域4中发现了一种致病变体.
- 这些发现强调了CADASIL中孤立精神病呈现的潜力.
结论:
- 应考虑在不对抗抑郁药物有反应的情感障碍患者中使用CADASIL,特别是有指示性MRI发现的患者.
- 对NOTCH3基因的基因分析对于诊断非典型的CADASIL呈现至关重要.
- 卡达西尔的表型变异性需要广泛的差异诊断方法.
相关概念视频
Electroconvulsive Therapy
22
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
22
Antidepressant Drugs: MAOIs and Other Agents
183
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
183
Alzheimer's Disease: Treatment
155
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
155


